DRTSW Alpha Tau Medical Ltd.
Price Chart
Executive Summary
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop and commercialize Alpha DaRT therapy for prostate cancer in the U.S. Tolmar will make an initial $15M manufacturing investment and a $20M equity investment at $11.99 per share (25% premium to 30-day VWAP), with up to $161.5M in milestone payments. The deal provides near-term capital and a commercial pathway for a key pipeline asset, but involves significant dilution (1.9% of shares outstanding) and milestone-dependent upside.
Actionable Insight
The collaboration provides near-term capital and validates Alpha DaRT's commercial potential, but the stock is likely to react positively to the premium equity investment and partnership with a strong urology commercial player. Traders should watch for upcoming clinical milestones and regulatory progress in prostate cancer, as well as potential dilution from the equity issuance.
Key Facts
- Tolmar receives exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer for 20 years from first commercial sale.
- Tolmar will invest $20M in Alpha Tau at $11.99/share (25% premium to 30-day VWAP), issuing 1,668,057 ordinary shares.
- Tolmar will pay $15M for construction of a new U.S. manufacturing facility.
- Up to $161.5M in clinical, regulatory, and commercial milestone payments for the first prostate cancer indication.
- Alpha Tau will supply Alpha DaRT to Tolmar at 60% of net sales price, subject to adjustments.
- Tolmar has an option to expand into bladder cancer with additional $5M equity investment and $5M manufacturing payment.
- The supply price to Tolmar is set at 60% of net sales, subject to adjustments.
- The collaboration agreement expires 20 years after first commercial sale of Alpha DaRT for prostate cancer in the U.S.
Financial Impact
Immediate $20M equity infusion at a 25% premium to VWAP, plus $15M manufacturing investment. Potential total milestone payments of up to $161.5M for the first prostate cancer indication, plus additional payments for bladder cancer option.
Risk Factors
- Dilution from the issuance of 1,668,057 ordinary shares (approximately 1.9% of outstanding shares).
- Milestone payments are contingent on achieving clinical and regulatory targets, which are uncertain.
- Alpha Tau retains manufacturing responsibility, exposing it to operational and cost risks.
- Tolmar can terminate the agreement without cause at any time.
- The company has a history of significant losses and limited operating revenue.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-064461 |
| Document: ea0293331-6k_alpha.htm | 0001213900-26-064461 |
| Document: 0001213900-26-064461-index-headers.html | 0001213900-26-064461 |
| Document: 0001213900-26-064461-index.html | 0001213900-26-064461 |
| Document: 0001213900-26-064461.txt | 0001213900-26-064461 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
2d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −0.40% | $2.00 (+96.08%) |
|
Jun 1, 2026
4d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −0.14% | $2.00 (+96.08%) |
|
May 18, 2026
18d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −1.04% | $2.00 (+96.08%) |
|
May 11, 2026
25d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▲ +0.14% | $2.00 (+96.08%) |
|
May 11, 2026
25d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▲ +0.14% | $2.00 (+96.08%) |
|
May 8, 2026
28d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −0.23% | $2.00 (+96.08%) |
|
May 8, 2026
28d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −0.23% | $2.00 (+96.08%) |
|
May 7, 2026
29d ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −0.83% | $2.00 (+96.08%) |
|
May 5, 2026
4w ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −1.38% | $2.00 (+96.08%) |
|
May 4, 2026
4w ago
|
6-K
| $1.02 $1.02 | · 0.00% | ▼ −0.80% | $2.00 (+96.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access